![Peer-Spectives artwork](https://is2-ssl.mzstatic.com/image/thumb/Podcasts125/v4/36/e6/62/36e6623f-f57c-fbd4-84fb-34267275b766/mza_11777352931460000686.jpg/100x100bb.jpg)
Myelofibrosis Remains Tough to Treat, But New Drugs Are Paving the Way
Peer-Spectives
English - November 11, 2022 22:14 - 13 minutes - 18.9 MBScience Education obr oncology cancer healthcare medical obroncology peerspectives robertfiglin Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: KRAS Inhibition in NSCLC: When, How, and Why?
Next Episode: Matching Breast Cancer Patients to Therapies: Here’s How
Listen as Gabriela Hobbs, MD, clinical director of the leukemia atMass General, talks with Bob Figlin, MD, the Steven Spielberg Family Chair in Hematology Oncology at Cedars-Sinai Cancer in Los Angeles, about the latest progress in the treatment of myelofibrosisand how she both assesses new patients and plans their treatment. New agents, including JAK2 inhibitors,are not curative but can have substantial effects on patients and open up further treatment options. Dr. Hobbs also talks about new drug classes on the horizon and what to expect at the upcoming ASH meeting.